Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan hails "significant" upside at Persimmon

(Sharecast News) - JPMorgan has reiterated an 'overweight' rating for Persimmon, saying that the housebuilder's medium-term targets provide "significant" earnings and valuation potential. The broker kept a positive recommendation on the stock with a 1,520p target price, suggesting further upside from Thursday morning's price of 1,304.5p (-1.1% on the day), despite the shares having outperformed the sector over 2025 so far.

The stock has gained 14% over the year-to-date compared with the wider sector up just 10%, but is still down 5% since the Labour government came into power last summer despite the launch a host of planning changes to support housebuilding.

As such, this still represents an "attractive opportunity for investors", according to JPM analyst Zaim Beekawa.

"As a reminder, Persimmon's mid-term objectives are to achieve 20% operating margins and ROCE; our scenario analysis indicates that, should Persimmon achieve these by 2029 (while continuing to grow the business), we could see earnings upside of 95%, while a simple correlation overlay of historical ROCE to historical P/TNAV, suggests upside of 45% to current valuation levels," Beekawa said.

The analyst also highlighted persimmon's "unappreciated" vertical integration capabilities, such the company using its own bricks, tiles and timber frames to save on build costs, along with the recent launch of its own shared equity products which differentiates it from competitors when it comes to affordability.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.